Importance of peroxisome proliferator-activated receptor-γ in hepatic ischemia/reperfusion injury in mice

Journal of Hepatology

Volumn 47, Issue 6, 2007, Pages 784-792

  Akahori, Takahiro ^a   Sho, Masayuki ^a   Hamada, Kaoru ^a   Suzaki, Yasue ^a   Kuzumoto, Yukiyasu ^a   Nomi, Takeo ^a   Nakamura, Shinji ^a   Enomoto, Koji ^a   Kanehiro, Hiromichi ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adhesion molecule; Apoptosis; Chemokine; Cytokine; Ischemia reperfusion injury; Neutrophil

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; LIVER ISCHEMIA; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SURVIVAL; UPREGULATION;

ANIMALS; APOPTOSIS; CYTOKINES; GENE EXPRESSION REGULATION; HEPATOCYTES; INFLAMMATION; LIVER DISEASES; MICE; NEUTROPHILS; PPAR GAMMA; REPERFUSION INJURY; SURVIVAL RATE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 35748937344     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.07.030     Document Type: Article

References (53)

1. Lemasters J.J., and Thurman R.G. Reperfusion injury after liver preservation for transplantation. Annu Rev Pharmacol Toxicol 37 (1997) 327-338
2. Huguet C., Gavelli A., and Bona S. Hepatic resection with ischemia of the liver exceeding one hour. J Am Coll Surg 178 (1994) 454-458
3. Jaeschke H. Preservation injury: mechanisms, prevention and consequences. J Hepatol 25 (1996) 774-780
4. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 284 (2003) G15-G26
5. Lentsch A.B., Kato A., Yoshidome H., McMasters K.M., and Edwards M.J. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 32 (2000) 169-173
6. Jaeschke H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1083-G1088
7. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
8. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
9. Michalik L., and Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol 10 (1999) 564-570
10. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4 (1999) 611-617
11. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
12. Mueller E., Drori S., Aiyer A., Yie J., Sarraf P., Chen H., et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277 (2002) 41925-41930
13. Chawla A., Schwarz E.J., Dimaculangan D.D., and Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135 (1994) 798-800
14. Stevenson R.W., McPherson R.K., Genereux P.E., Danbury B.H., and Kreutter D.K. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40 (1991) 1268-1274
15. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274 (1999) 6718-6725
16. Fujiwara T., Okuno A., Yoshioka S., and Horikoshi H. Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44 (1995) 486-490
17. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 92 (2003) 34J-41J
18. Abdelrahman M., Sivarajah A., and Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65 (2005) 772-781
19. Michalik L., and Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 116 (2006) 598-606
20. Cuzzocrea S. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury. Vascul Pharmacol 41 (2004) 187-195
21. Sivarajah A., Chatterjee P.K., Patel N.S., Todorovic Z., Hattori Y., Brown P.A., et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23 (2003) 267-276
22. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469
23. Ito K., Shimada J., Kato D., Toda S., Takagi T., Naito Y., et al. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothorac Surg 25 (2004) 530-536
24. Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARγ-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 22 (2005) 278-282
25. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16 (2002) 1027-1040
26. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
27. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122 (2002) 1924-1940
28. Miyahara T., Schrum L., Rippe R., Xiong S., Yee Jr. H.F., Motomura K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715-35722
29. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466-478
30. Kuzumoto Y., Sho M., Ikeda N., Hamada K., Mizuno T., Akashi S., et al. Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice. Hepatology 42 (2005) 608-617
31. Colletti L.M., Remick D.G., Burtch G.D., Kunkel S.L., Strieter R.M., and Campbell Jr. D.A. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 85 (1990) 1936-1943
32. Suzuki S., and Toledo-Pereyra L.H. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J Surg Res 57 (1994) 253-258
33. Langdale L.A., Wilson L., Jurkovich G.J., and Liggitt H.D. Effects of immunomodulation with interferon-gamma on hepatic ischemia-reperfusion injury. Shock 11 (1999) 356-361
34. Lentsch A.B., Yoshidome H., Cheadle W.G., Miller F.N., and Edwards M.J. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. Hepatology 27 (1998) 1172-1177
35. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Patel N.S., Di Paola R., et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140 (2003) 366-376
36. Okada M., Yan S.F., and Pinsky D.J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16 (2002) 1861-1868
37. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 152 (1998) 423-430
38. Afford S.C., Fisher N.C., Neil D.A., Fear J., Brun P., Hubscher S.G., et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 186 (1998) 82-89
39. Bone-Larson C.L., Hogaboam C.M., Evanhoff H., Strieter R.M., and Kunkel S.L. IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J Immunol 167 (2001) 7077-7083
40. Ghose R., Mulder J., von Furstenberg R.J., Thevananther S., Kuipers F., and Karpen S.J. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J Hepatology 46 (2007) 115-123
41. Farhood A., McGuire G.M., Manning A.M., Miyasaka M., Smith C.W., and Jaeschke H. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 57 (1995) 368-374
42. Yadav S.S., Howell D.N., Steeber D.A., Harland R.C., Tedder T.F., and Clavien P.A. P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology 29 (1999) 1494-1502
43. Martinez-Mier G., Toledo-Pereyra L.H., and Ward P.A. Adhesion molecules in liver ischemia and reperfusion. J Surg Res 94 (2000) 185-194
44. Goetze S., Bungenstock A., Czupalla C., Eilers F., Stawowy P., Kintscher U., et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARγ-ligands. Hypertension 40 (2002) 748-754
45. Schulze-Bergkamen H., Schuchmann M., Fleischer B., and Galle P.R. The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?. J Hepatol 44 (2006) 984-993
46. Soller M., Tautenhahn A., Brune B., Zacharowski K., John S., Link H., et al. Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis. J Leukoc Biol 79 (2006) 235-243
47. Bodles A.M., Varma V., Yao-Borengasser A., Phanavanh B., Peterson C.A., McGehee Jr. R.E., et al. Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res 47 (2006) 2080-2088
48. Lee K.S., Kim S.R., Park S.J., Park H.S., Min K.H., Jin S.M., et al. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 118 (2006) 120-127
49. Sener G., Sehirli A.O., Gedik N., and Dulger G.A. Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 33 (2007) 587-593
50. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126 (2004) 873-885
51. Leclercq I.A., Sempoux C., Starkel P., and Horsmans Y. Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut 55 (2006) 1020-1029
52. Yavrom S., Chen L., Xiong S., Wang J., Rippe R.A., and Tsukamoto H. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280 (2005) 40650-40659
53. Hazra S., Xiong S., Wang J., Rippe R.A., Krishna V., Chatterjee K., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279 (2004) 11392-11401